T3D Therapeutics Receives FDA Approval for a 6-Month, Open-Label Extension to its Phase 2a Trial of T3D-959 for Treatment of Mild to Moderate Alzheimer’s Disease

T3D Therapeutics has received FDA approval for an open-label, 26-week extension study in mild to moderate Alzheimer’s disease patients extending its Phase 2a feasibility study of T3D-959, an investigational new drug candidate that has the potential to be transformative by slowing, stopping or reversing Alzheimer’s disease. Read more

The release as fetched from its publisher. t3dtherapeutics.com ↗